CAMBIA, Zipsor, Lazanda and Acuform are registered trademarks of Depomed, Inc.
In 2015, Depomed's Gralise
Will Earn Decision Resources' Proprietary Gold-Standard Status for Painful Diabetic Neuropathy, According to Findings from Decision Resources
The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to, those related to the commercialization of NUCYNTA ER, NUCYNTA, Gralise
, CAMBIA, Zipsor and Lazanda, Depomed's financial outlook for 2015 and expectations regarding financial results and potential business opportunities and other risks detailed in the company's Securities and Exchange Commission filings, including the company's Annual Report on Form 10-K for the year ended December 31, 2014 and most recent Quarterly Report on Form 10-Q.
In October, we hit all-time weekly prescription highs for NUCYNTA ER, Gralise
and Cambia, reflecting the outstanding work of our sales force across the entire product line.
They are Gralise
(gabapentin extended release), Qutenza (capsaicin), Lyrica (pregabalin), Neurontin (gabapentin), and Lidoderm/Versatis (lidocaine).
As another example, since launching our proprietary Gralise
product in the fourth quarter of 2011, we have grown quarterly net sales of Gralise